Literature DB >> 25421578

Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.

Mei Yee Koh1, Vuvi Nguyen2, Robert Lemos3, Bryant G Darnay2, Galina Kiriakova2, Mena Abdelmelek2, Thai H Ho4, Jose Karam5, Federico A Monzon6, Eric Jonasch5, Garth Powis3.   

Abstract

Clear-cell renal cell cancer (CRCC) is initiated typically by loss of the tumor-suppressor VHL, driving constitutive activation of hypoxia-inducible factor-1 (HIF1) and HIF2. However, whereas HIF1 has a tumor-suppressor role, HIF2 plays a distinct role in driving CRCC. In this study, we show that the HIF1α E3 ligase hypoxia-associated factor (HAF) complexes with HIF2α at DNA to promote HIF2-dependent transcription through a mechanism relying upon HAF SUMOylation. HAF SUMOylation was induced by hypoxia, whereas HAF-mediated HIF1α degradation was SUMOylation independent. HAF overexpression in mice increased CRCC growth and metastasis. Clinically, HAF overexpression was associated with poor prognosis. Taken together, our results show that HAF is a specific mediator of HIF2 activation that is critical for CRCC development and morbidity. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25421578      PMCID: PMC4297521          DOI: 10.1158/0008-5472.CAN-13-2190

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

Review 1.  Concepts in sumoylation: a decade on.

Authors:  Ruth Geiss-Friedlander; Frauke Melchior
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

Review 2.  VHL and HIF signalling in renal cell carcinogenesis.

Authors:  Marcella M Baldewijns; Iris J H van Vlodrop; Peter B Vermeulen; Patricia M M B Soetekouw; Manon van Engeland; Adriaan P de Bruïne
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

3.  Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.

Authors:  Kevin J Turner; John W Moore; Adam Jones; Claire F Taylor; Darren Cuthbert-Heavens; Cheng Han; Russell D Leek; Kevin C Gatter; Patrick H Maxwell; Peter J Ratcliffe; David Cranston; Adrian L Harris
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

4.  Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation.

Authors:  Betty Lamothe; Arnaud Besse; Alejandro D Campos; William K Webster; Hao Wu; Bryant G Darnay
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

5.  Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype.

Authors:  Linda Holmquist-Mengelbier; Erik Fredlund; Tobias Löfstedt; Rosa Noguera; Samuel Navarro; Helén Nilsson; Alexander Pietras; Johan Vallon-Christersson; Ake Borg; Katarina Gradin; Lorenz Poellinger; Sven Påhlman
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

6.  Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

Authors:  Rosamonde E Banks; Prasanna Tirukonda; Claire Taylor; Nick Hornigold; Dewi Astuti; Dena Cohen; Eamonn R Maher; Anthea J Stanley; Patricia Harnden; Adrian Joyce; Margaret Knowles; Peter J Selby
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

7.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

Authors:  John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A Greenberg; Keith T Flaherty; W Kimryn Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

8.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Authors:  Michael Zimmer; Darrell Doucette; Naila Siddiqui; Othon Iliopoulos
Journal:  Mol Cancer Res       Date:  2004-02       Impact factor: 5.852

Review 9.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.

Authors:  Brian Keith; Randall S Johnson; M Celeste Simon
Journal:  Nat Rev Cancer       Date:  2011-12-15       Impact factor: 60.716

10.  A proteomic study of SUMO-2 target proteins.

Authors:  Alfred C O Vertegaal; Stephen C Ogg; Ellis Jaffray; Manuel S Rodriguez; Ronald T Hay; Jens S Andersen; Matthias Mann; Angus I Lamond
Journal:  J Biol Chem       Date:  2004-06-02       Impact factor: 5.157

View more
  17 in total

Review 1.  New genetic and physiological factors for excessive erythrocytosis and Chronic Mountain Sickness.

Authors:  Francisco C Villafuerte
Journal:  J Appl Physiol (1985)       Date:  2015-08-13

2.  Hydroxyl-HIF2-alpha is potential therapeutic target for renal cell carcinomas.

Authors:  Takahiro Isono; Tokuhiro Chano; Tetsuya Yoshida; Susumu Kageyama; Akihiro Kawauchi; Masafumi Suzaki; Takeshi Yuasa
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

3.  Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.

Authors:  Yangsook Song Green; Timothy Sargis; Ethan Conrad Reichert; Eleanor Rudasi; Daniel Fuja; Eric Jonasch; Mei Yee Koh
Journal:  Mol Cancer Res       Date:  2019-01-31       Impact factor: 5.852

Review 4.  Role of Intestinal HIF-2α in Health and Disease.

Authors:  Sadeesh K Ramakrishnan; Yatrik M Shah
Journal:  Annu Rev Physiol       Date:  2015-11-19       Impact factor: 19.318

5.  Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.

Authors:  Sophie J Cowman; Daniel G Fuja; Xian-De Liu; Rebecca S Slack Tidwell; Neelima Kandula; Deepika Sirohi; Archana M Agarwal; Lyska L Emerson; Sheryl R Tripp; Jeffrey S Mohlman; Miekan Stonhill; Guillermina Garcia; Christopher J Conley; Adam A Olalde; Timothy Sargis; Adela Ramirez-Torres; Jose A Karam; Christopher G Wood; Kanishka Sircar; Pheroze Tamboli; Kenneth Boucher; Benjamin Maughan; Benjamin T Spike; Thai H Ho; Neeraj Agarwal; Eric Jonasch; Mei Yee Koh
Journal:  Clin Cancer Res       Date:  2020-06-25       Impact factor: 12.531

Review 6.  Hypoxia-inducible factor as an angiogenic master switch.

Authors:  Takuya Hashimoto; Futoshi Shibasaki
Journal:  Front Pediatr       Date:  2015-04-24       Impact factor: 3.418

Review 7.  DUBs, New Members in the Hypoxia Signaling clUb.

Authors:  Amelie S Schober; Edurne Berra
Journal:  Front Oncol       Date:  2016-03-09       Impact factor: 6.244

8.  HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.

Authors:  Xiang-Me Lai; Shu-Yu Liu; Yi-Ta Tsai; Guang-Huan Sun; Sun-Yran Chang; Shih-Ming Huang; Tai-Lung Cha
Journal:  Oncotarget       Date:  2017-07-25

9.  Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection.

Authors:  Yong Li; Chuanlong Zhu; Faxi Wang; Tiantian Zhu; Jun Li; Shufeng Liu; Fei Xiao
Journal:  Mediators Inflamm       Date:  2016-12-18       Impact factor: 4.711

10.  The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.

Authors:  Damien Ambrosetti; Maeva Dufies; Bérengère Dadone; Matthieu Durand; Delphine Borchiellini; Jean Amiel; Jacques Pouyssegur; Nathalie Rioux-Leclercq; Gilles Pages; Fanny Burel-Vandenbos; Nathalie M Mazure
Journal:  PLoS One       Date:  2018-02-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.